ArticleScientific reports2026
Identification and validation of BLK and OSBPL10 as diagnostic and prognostic biomarkers for nasopharyngeal carcinoma through machine learning algorithms.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Despite substantial advances in radiotherapy and chemotherapy for nasopharyngeal carcinoma (NPC), a subset of patients still develops metastasis or recurrence following initial treatment. Additionally, the atypical early symptoms of NPC often lead to clinical misdiagnosis or missed diagnosis, resulting in late diagnosis and unfavorable prognosis. Thus, novel diagnostic biomarkers are urgently required. By integrating five GEO datasets and applying four machine learning models, namely LASSO, SVM-RFE, XGBOOST, and mRMR, this study identified two key NPC-related genes, BLK and OSBPL10. Bioinformatic analyses revealed that both genes are significantly downregulated in NPC, and this downregulation pattern was further validated in the GSE61218 dataset. Notably, receiver operating characteristic (ROC) curves confirmed their high diagnostic efficacy for NPC. BLK and OSBPL10 are involved in pathways such as B-cell receptor signaling and lipid metabolic regulation, respectively, and are closely associated with the infiltration of various immune cells. Immunohistochemical staining validation further confirmed that the protein expression levels of BLK and OSBPL10 are downregulated in NPC tissues compared with those in benign lesions, and their low expression is strongly associated with the poor prognosis of patients. In summary, these findings indicated that BLK and OSBPL10 may serve as candidate biomarkers for NPC diagnosis and prognosis, although further validation in independent cohorts is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.